Clinical trial · Observational
Dynamic Whole Body PET/ MRI
Dynamic Whole Body Positron Emission Tomography/ Magnetic Resonance Imaging
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study never initiated, should have been removed prior to last update.
Summary
Brief summary (as posted)
Prostate cancer is the third most common cause of cancer death in men. Most patients with localized prostate cancer will be cured with surgery or radiation therapy, but up to 35% of patients will have their prostate cancer return.Current conventional imaging modalities have limitations particularly at low prostate specific antigen levels. This study proposes to use 68Ga-HTK03149 Dynamic Whole Body (DWB) Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) scans which targets prostate-specific membrane antigens (PSMA) to detect where in the body the prostate cancer has recurred.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-HTK03149 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 68Ga-HTK03149 PET/MRI DWB scan
- description
- All participants will undergo the same procedures listed in "Detailed Description" in the protocol section.
- interventionNames
- Drug: 68Ga-HTK03149
Primary outcomes (1)
- measure
- Sensitivity of Dynamic Whole Body 68Ga-HTK03149PET/MRI imaging in the assessment of high risk prostate cancer.
- timeFrame
- 5 years after 68Ga-HTK03149DWB PET/MRI scan
- description
- Determination of sensitivity when compared with pathology reports
Secondary outcomes (2)
- measure
- Accuracy of combined DWB PET/MRI to assess the extent of prostate cancer
- timeFrame
- 5 years after 68Ga-HTK03149 DWB PET/MRI scan
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 19 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with biopsy-proven high risk prostate cancer (UCSF/CAPRA score 6 or higher) scheduled for radical prostatectomy. * Able to not use the washroom for the duration of the dynamic imaging scanning. * Eastern Cooperative Oncology Group performance status of 2 or less. * Able to lie supine for the required duration of the scans Exclusion Criteria: * Meet the exclusion criteria for the appropriate standard of care imaging. * Experience claustrophobia. * Subjects with severe renal disease or acutely deteriorating renal function (eGRF\<30 mL/min) * Subjects may not take part in this study if they have a pacemaker, an implanted defibrillator, or certain other implanted electronic or metallic devices, shrapnel, or other metal.
References
Publications (0)
Data not yet available